Any feedback?
Literature summary extracted from
- Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors (TRAIN) study (2009), Am. Heart J., 157, 334e1-334e8.
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.15.1 | fosinopril | administered as a prodrug and then rapidly converted by the liver and the gastrointestinal mucosa to the active form fosinoprilat | Homo sapiens |  |
| 3.4.15.1 | additional information | angiotensin-converting enzyme inhibition does not significantly modify major biomarkers of inflammation, hemostasis, and endothelial function, e.g. C-reactive protein, interleukin 6, plasminogen activator inhibitor 1, vascular cell adhesion molecule 1, and endothelin 1, while angiotensin II levels are reduced, overview | Homo sapiens |
Natural Substrates/ Products (Substrates)
| EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.15.1 | angiotensin I + H2O | Homo sapiens | i.e. DRVYIHPFHL | angiotensin II + His-Leu | i.e. DRVYIHPF | ? | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.15.1 | Homo sapiens | - |
- |
- |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.15.1 | angiotensin I + H2O | i.e. DRVYIHPFHL | Homo sapiens | angiotensin II + His-Leu | i.e. DRVYIHPF | ? | |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.15.1 | ACE | - |
Homo sapiens |
| 3.4.15.1 | angiotensin-converting enzyme | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
